Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper (Articolo in rivista)

Type
Label
  • Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper (Articolo in rivista) (literal)
Anno
  • 2014-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1111/all.12383 (literal)
Alternative label
  • Pfaar O.; Demoly P.; Gerth Van Wijk R.; Bonini S.; Bousquet J.; Canonica G.W.; Durham S.R.; Jacobsen L.; Malling H.J.; Mosges R.; Papadopoulos N.G.; Rak S.; Rodriguez Del Rio P.; Valovirta E.; Wahn U.; Calderon M.A. (2014)
    Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper
    in Allergy (Cph.)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Pfaar O.; Demoly P.; Gerth Van Wijk R.; Bonini S.; Bousquet J.; Canonica G.W.; Durham S.R.; Jacobsen L.; Malling H.J.; Mosges R.; Papadopoulos N.G.; Rak S.; Rodriguez Del Rio P.; Valovirta E.; Wahn U.; Calderon M.A. (literal)
Pagina inizio
  • 854 (literal)
Pagina fine
  • 867 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.scopus.com/inward/record.url?eid=2-s2.0-84902083555&partnerID=q2rCbXpz (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 69 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 7 (literal)
Note
  • Scopu (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Center for Rhinology and Allergology Wiesbaden, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Mannheim, Germany; Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France; Sorbonne Universités, UPMC Paris 06, IPLESP Equipe EPAR, Paris, France; Section of Allergology, Department of Internal Medicine, Erasmus MC, Rotterdam, Netherlands; Second University of Naples, Institute of Translational Pharmacology, Italian National Research Council (IFT-CNR), Rome, Italy; 1018 Respiratory and Environmental Epidemiology Team, INSERM CESP Centre for Research in Epidemiology and Population Health, Villejuif, France; Respiratory Diseases and Allergy Clinic, University of Genova, IRCCS AOU San Martino, Genova, Italy; Section of Allergy and Clinical Immunology, National Heart and Lung Institute Imperial College, London, United Kingdom; ALC, Allergy Learning and Consulting, Copenhagen, Denmark; Allergy Clinic, University Hospital Gentofte, Copenhagen, Denmark; Institute of Medical Statistics Informatics and Epidemiology (IMSIE), University of Cologne, Cologne, Germany; Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; Centre for Paediatrics and Child Health, Institute of Human Development, University of Manchester, Manchester, United Kingdom; Department of Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Goteborg, Sweden; Department of Allergy, Niño Jesús University Hospital, Madrid, Spain; Department of Clinical Allergology and Pulmonary Diseases, University of Turku, Finland; Suomen Terveystalo Allergy Clinic, Turku, Finland; Department for Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany (literal)
Titolo
  • Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: An EAACI Position Paper (literal)
Abstract
  • Background Allergen immunotherapy (AIT) has been thoroughly documented in randomized controlled trials (RCTs). It is the only immune-modifying and causal treatment available for patients suffering from IgE-mediated diseases such as allergic rhinoconjunctivitis, allergic asthma and insect sting allergy. However, there is a high degree of clinical and methodological heterogeneity among the endpoints in clinical studies on AIT, for both subcutaneous and sublingual immunotherapy (SCIT and SLIT). At present, there are no commonly accepted standards for defining the optimal outcome parameters to be used for both primary and secondary endpoints. Methods As elaborated by a Task Force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) Immunotherapy Interest Group, this Position Paper evaluates the currently used outcome parameters in different RCTs and also aims to provide recommendations for the optimal endpoints in future AIT trials for allergic rhinoconjunctivitis. Results Based on a thorough literature review, the TF members have outlined recommendations for nine domains of clinical outcome measures. As the primary outcome, the TF recommends a homogeneous combined symptom and medication score (CSMS) as a simple and standardized method that balances both symptoms and the need for antiallergic medication in an equally weighted manner. All outcomes, grouped into nine domains, are reviewed. Conclusion A standardized and globally harmonized method for analysing the clinical efficacy of AIT products in RCTs is required. The EAACI TF highlights the CSMS as the primary endpoint for future RCTs in AIT for allergic rhinoconjunctivitis. © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it